Major pharmaceutical companies are increasingly adopting artificial intelligence to speed up drug discovery and reduce research costs. Industry leaders report that AI-driven platforms are helping identify potential drug candidates faster, optimize clinical trial design, and…

Read more

The European Union has reached a landmark agreement to reform drug regulations, aiming to speed up patient access to medicines across the bloc. The new framework revises data and market exclusivity rules, supports antibiotic innovation, and strengthens supply…

Read more

As a practising doctor in India, I’m encouraged by the latest development: Dr Reddy’s Laboratories has signed an exclusive licensing agreement with Australia-based Immutep to market a promising new cancer drug — a move that could expand therapeutic options for patients across the…

Read more

As a doctor, I’m genuinely excited about a recent milestone in Indian medicine — the launch of Nafithromycin, the first antibiotic discovered, developed and clinically validated entirely in India.

This antibiotic — marketed as Miqnaf — promises a short, once-daily, three-day treatment for…

Read more

The United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Zaynich, a first-in-class antibiotic developed by Wockhardt Ltd., marking a historic milestone — it’s the first time an Indian…

Read more

A groundbreaking approval: the U.S. FDA has cleared Itvisma, a one-time gene therapy for patients aged 2 years and older with Spinal Muscular Atrophy (SMA), offering a potential lifeline for those previously beyond the reach of existing treatments.

This week, the U.S. Food and Drug Administration (FDA) approved Plozasiran (brand name: Redemplo) — a new siRNA therapy for Familial Chylomicronemia Syndrome (FCS), a rare genetic disorder that causes dangerously high triglyceride levels.

✅ What This Means from a Doctor’s Perspective

• For…

Read more

As a practising physician in India, I’m thrilled by the recent announcement of Nafithromycin — the first antibiotic discovered and developed entirely within India.

For many of us on the front lines, antimicrobial resistance is a growing nightmare: rising…

Read more

I’m deeply concerned—but also cautiously hopeful—about the recent anti‑dumping probe India has launched into imports of Ethambutol Hydrochloride, a key API used in TB drugs.

From a medical standpoint:

• Access to TB medicines is non-negotiable—we rely on affordable, consistent supply to treat…

Read more

As a clinician, the latest move from drug regulators raises both concern and hope. The DCGI has issued a final directive: all pharma manufacturing plants must fully comply with updated Good Manufacturing Practice (GMP) rules by 31 December 2025, or face closure.

Why…

Read more

As a physician who increasingly relies on digital health tools, I find India’s latest move hugely significant: the CDSCO has published a draft guidance document for medical-device software (SaMD and SiMD), including AI/ML-based applications.

What this means for us at…

Read more

As a doctor, here’s why this matters for all of us in healthcare:

• Stronger…

Read more

The Indian government has reduced the Goods & Services Tax (GST) on a wide range of medical devices to 5% effective from 22 September 2025.

As a physician, this move signals both opportunity and responsibility:

• Patient affordability improves – With lower tax, devices such as diagnostics kits,…

Read more

As a physician, I pay attention not only to new medicines but also to how the pharma industry is evolving — because stronger companies often mean better supply, better innovation and improved access for my patients. Glenmark Pharmaceuticals…

Read more

👨‍⚕️ From a Doctor’s Perspective

• Patient access improvement: Lowering the price means…

Read more

As a practicing physician, I believe meaningful change in healthcare doesn’t just come from new drugs — it comes from smarter systems too. Recently, the Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam introduced the “i-Passport”, a streamlined gateway for med-tech and health-tech…

Read more

Novo Nordisk has cut the Indian price of its weight-loss drug Wegovy (semaglutide) by up to 37%.
Why this matters:

• Affordability is a major barrier in real-world practice; price reductions can increase adoption and allow more patients access.

• However, it also raises expectations: if we use the drug…

Read more

As a practising physician, I’m excited by a new development that directly impacts the front-line of patient care: a team from Blackfrog Technologies in Manipal has launched the EMON-25, an intelligent retrofit system that converts regular medical refrigerators into…

Read more

As a physician, patient safety is always front and centre—and recent regulatory action in India demands our attention. The Central Drugs Standard Control Organisation (CDSCO) has mandated that all pharmaceutical manufacturers must meet international standards by January 1, 2026—following a tragic…

Read more

Two recent announcements stand out for us in clinical practice:

• Finerenone (brand name Kerendia) has just received expanded approval in India for treating adult patients with heart‐failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). This opens up treatment for a…

Read more

As a clinician, I welcome any move that speeds access to safe, affordable equipment—but only if safety keeps pace. India will now allow self-certification for over a thousand low- to moderate-risk medical devices (think stethoscopes, wheelchairs, swabs, scissors). The aim…

Read more

As a physician, recent regulatory action in India feels like a wake-up call. Senior officials announced that any pharma firm found submitting fake or misleading documents to obtain licences will face immediate bans under new amendments to the Central Drugs…

Read more

As a physician, the recent developments in India’s pharmaceutical industry have been deeply unsettling. Authorities have issued a hard-hitting advisory after discovering that multiple manufacturing facilities failed to test every batch of raw materials or…

Read more

In my practice, the moment a new drug emerges from trials into the real world, everything changes. While randomized controlled trials give us foundational safety and efficacy, it’s real-world evidence (RWE) that reveals how treatments perform in everyday settings—across comorbidities,…

Read more

In my daily practice, I’ve noticed how quickly the dynamic between pharmaceutical companies and physicians has shifted—and it’s all moving online. These days, digital roundtables are becoming the primary forum for meaningful engagement.

Instead of crowded conference halls and…

Read more

As a doctor, I’ve seen a major transformation in how the pharmaceutical industry connects with healthcare professionals — and it’s all thanks to virtual meetings. What used to be long in-person sessions or conferences has now evolved into focused, efficient digital…

Read more

As a practicing doctor, I’ve come to realize that no single clinician can hold all the answers — especially in today’s rapidly evolving medical landscape. That’s where physician networking communities are proving transformative.

Platforms like HealthSocial are not just…

Read more

As a doctor, I’ve always believed that the foundation of good healthcare lies in communication — between clinicians, patients, researchers, and the pharmaceutical industry. Yet, for decades, that communication has often been fragmented and slow. Today, Artificial…

Read more

As a doctor, I’ve witnessed how digital collaboration platforms are transforming the healthcare industry. Platforms like HealthSocial allow doctors, researchers, and pharma professionals to exchange ideas instantly — breaking silos that once slowed progress.

Whether it’s…

Read more

As a doctor, I see this week’s Supreme Court verdict — allowing Natco Pharma to launch its generic version of Risdiplam — as a landmark moment for both patients and the healthcare ecosystem. Risdiplam is a life-changing drug for Spinal Muscular Atrophy…

Read more

As a clinician deeply invested in both patient safety and pharmaceutical integrity, recent events surrounding contaminated cough syrups in India have shaken me to the core. This isn’t just “another pharma scandal” — it’s a stark warning that regulatory gaps, quality lapses,…

Read more

As a doctor, I’ve always viewed India’s pharmaceutical sector with a sense of pride — it’s often called “the pharmacy of the world.” Over the past decade, Indian pharma exports have grown remarkably, supplying affordable and quality medicines to more than 200…

Read more

As a practising doctor, I see the rapid transformation of India’s pharmaceutical industry not just as industry news, but as something that directly impacts patient care, prescribing habits, and trust in our healthcare system.

Affordability remains a key focus. The…

Read more

As a physician who often deals with shortages or long lead times for imaging and critical care equipment, this update is very encouraging. Premier Medical Systems (Medisys), one of India’s earliest medical-equipment makers, has secured a letter of…

Read more

India’s medical device market is set to expand from USD 6.82 billion in 2025 to approximately USD 12.57 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.00%. This growth is driven by increased healthcare investment, government support, and…

Read more

The Central Drugs Standard Control Organisation (CDSCO) has approved eight new medicines in 2025, marking a significant step forward in India’s healthcare sector. These approvals encompass a range of…

Read more

In Hyderabad, the LV Prasad Eye Institute (LVPEI) ran a study in children with retinoblastoma (a rare but serious eye cancer). Traditionally, recurrences or resistant tumors are treated with intravitreal injections of melphalan, but at higher doses that can damage…

Read more

In oncology and autoimmune care, I often see patients forced to discontinue treatment because the original biologic drug is too expensive. This is where biosimilars — near-identical versions of complex biologics — are changing lives in India.

Recently, Indian pharma…

Read more

Recently, one of my heart patients showed me how his smartwatch had picked up irregular beats before he even felt symptoms. That moment reminded me how far we’ve come — and how much further we can go.

Wearables today track heart rate, sleep, oxygen levels, and even stress. But what…

Read more

One change I’ve noticed in recent years is that prescribing is no longer just about choosing a drug — it’s about choosing the right drug for the right patient, backed by a diagnostic test. These are called companion diagnostics, and they’re becoming more common in cancer, infectious…

Read more

When I look back at how I practiced medicine even a decade ago, the changes in our industry feel nothing short of remarkable.

Take diagnostics — once, waiting for CT or MRI reports could delay treatment decisions. Today, with faster imaging and AI-assisted reporting, I often get actionable insights within…

Read more

As a doctor, I sometimes forget how much of the medicines I prescribe today are shaped by AI working behind the scenes in pharma. It’s no longer just futuristic — I see it in daily practice.

Consider antibiotics. With resistance rising, I often worry if I’m choosing the right one. Now, pharma…

Read more

In my practice, I prescribe generics frequently. A few months ago, I had a patient with high cholesterol who could not afford a branded statin. I shifted him to a generic version. Within 6 weeks, his LDL had dropped beautifully, and his follow-up labs looked great.

But another patient on a…

Read more

Several changes are underway that affect us in clinical practice:

• The DCGI / CDSCO is pushing faster drug approvals, especially for rare disease therapies and advanced treatments (like gene therapies).

• Drug licensing systems are being digitized: state + central…

Read more

Take, for example,…

Read more

As doctors, we often focus on lab…

Read more

Read more

A new global survey published in The Lancet highlights that over 60% of doctors report high levels of burnout, citing long hours, administrative overload, and staffing shortages. Personally, I see colleagues struggling with exhaustion and sometimes questioning whether to continue in clinical practice. Burnout not only affects…

Read more

The Indian healthcare sector is rapidly embracing artificial intelligence, with adoption rates now surpassing FMCG and manufacturing.

In hospitals, AI is being used for diagnostics (image analysis, CT/X-ray interpretation), predictive analytics (anticipating disease outbreaks, patient deterioration), and…

Read more

Read more